ArticleMolecular biology reports2020
BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic.
Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review.JCO global oncology · 2021Pooled it
- Identification of a False-positive Multiplex Ligationdependent Probe Amplification Result inAnnals of laboratory medicine · 2024Article
- Unexpected finding of a rare pathogenic germline BRCA1 variant in an intrahepatic cholangiocarcinoma using the Oncomine Focus DNA assay: clinical and diagnostic implications.Molecular biology reports · 2023Article
- Changes in the quality of cancer care as assessed through performance indicators during the first wave of the COVID-19 pandemic in 2020: a scoping review.BMC health services research · 2022Article
- COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response.BMC infectious diseases · 2022Article
- The Impact of the SARS-CoV-2 Pandemic on Healthcare Provision in Italy to non-COVID Patients: a Systematic Review.Mediterranean journal of hematology and infectious diseases · 2022Review
- Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation.Molecular biology reports · 2021Review
- Recent advances in detection technologies for COVID-19.Talanta · 2021Review
- Predictions of cancer mortality in Europe in 2021: room for hope in the shadow of COVID-19?Annals of oncology : official journal of the European Society for Medical Oncology · 2021Article
- BRCA testing delay during the COVID-19 pandemic: How to act?Molecular biology reports · 2021Article
- A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know.Translational lung cancer research · 2020Review
- Challenges and issues surrounding the use for translational research of human samples obtained during the COVID-19 pandemic from lung cancer patients.Translational lung cancer research · 2020Review
- Impact of COVID-19 on cancer diagnosis and management in Slovenia - preliminary results.Radiology and oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first person-to-person transmission of the 2019-novel coronavirus in Italy on 21 February 2020 led to an infection chain that represents one of the largest known COVID-19 outbreaks outside Asia. Hospitals have been forced to reorganized their units in response to prepare for an unforeseen healthcare emergency. In this context, our laboratory (Molecular and Genomic Diagnostics Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) re-modulated its priorities by temporarily interrupting most of the molecular tests guaranteeing only those considered "urgent" and not postponable. In particular, this paper details changes regarding the execution of germline BRCA (gBRCA) testing in our laboratory. A substantial reduction in gBRCA testing (about 60%) compared to the first 2 months of the current year was registered, but the requests have not been reset. The requesting physicians were mainly gynaecologists and oncologists. These evidences further emphasize the new era of gBRCA testing in the management of cancer patients and confirms definitively the integration of gBRCA testing/Next Generation Sequencing (NGS) into clinical oncology. Finally, a re-organization of gBRCA testing in our Unit, mainly related to delayed and reduced arrival of tests was necessary, ensuring, however, a high-quality standard and reliability, mandatory for gBRCA testing in a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.